References
- Bailer JA. (1988) Testing for the quality of area under the curves when using destructive measurement techniques. J Pharma Biopharm 16:303–309.
- Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, Scatina J. (2009). Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. Drug Metab Dispos 37:1219–1225.
- Ermer J, McKeand W, Sullivan P, Parker V and Orczyk G (2003) Bazedoxifene acetate dose proportionality in healthy, postmenopausal women. Clin Pharmacol Ther 73:P46.
- Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. (2007). Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 24:361–379.
- Gennari L, Merlotti D, De Paola V, Martini G, Nuti R. (2008). Bazedoxifene for the prevention of postmenopausal osteoporosis. Ther Clin Risk Manag 4:1229–1242.
- Gibaldi and D. Perrier, Pharmacokinetics. 2nd edition. New York: Marcel-Dekker, Inc., 1982.
- Gruber C, Gruber D. (2004). Bazedoxifene (Wyeth). Curr Opin Investig Drugs 5:1086–1093.
- Hochner-Celnikier D. (1999). Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23–29.
- Jeong EJ, Liu Y, Lin H, Hu M. (2005). Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785–794.
- Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700.
- Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. (2005). Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999–4008.
- Komm BS, Lyttle CR. (2001). Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 949:317–326.
- Lindstrom TD, Whitaker NG, Whitaker GW. (1984). Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 14:841–847.
- Miller CP, Harris HA and Komm BS. (2002) Bazedoxifene acetate. Drugs Future 27:117–121.
- Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD. (2008). Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 23:525–535.
- Mizuma T. (2009). Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378:140–141.
- Nickerson DF, Tess DA, Toler SM. (1997). First-pass metabolism and biliary recirculation of droloxifene in the female Sprague-Dawley rat. Xenobiotica 27:257–264.
- Patat A, McKeand W, Baird Bellaire S, Ermer J, LeCoz F. (2003) Absolute bioavailability of bazedxoifene acetate in healthy postmenopausal women. Clin Pharmacol Ther 73:P43
- Ronkin S, Northington R, Baracat E, Nunes MG, Archer DF, Constantine G, Pickar JH. (2005). Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 105:1397–1404.
- Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. (2008). Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 23:1923–1934.
- Ullrich JW and Miller PC. (2006) Estrogen receptor modulator review. Expert opin Ther Patents 16:559–572.